Biotech takes aim at large anti-estrogen markets

Article Abstract:

Pharmaceutical companies around the world are competing against each other in a race to develop the next generation of selective estrogen receptor modulator (SERM) drugs. SERMs are descendents of tamoxifen, an anti-estrogen compound used to treat breast cancer and both the biotech and pharma companies are focused on re-engineering tamoxifen to generate SERM derivatives that retain and expand its benefit while reducing the risks.

Estrogen, Estrogen receptors

---

Stem cell therapy or snake oil?

Article Abstract:

The US Food and Drug Administration (FDA) gave the permission to the Palo Alto, California-based Company, Stem Cells, to inject fetal neural stem cells into the brains of children suffering from Battan disease, a devastating neurodegenerative disorder. Critics claim that these researchers are risking grave harm to both research and patients, by administering unproven cell therapies to patients.

Government regulation, Licensing, certification and accreditation, Neural therapy (Alternative medicine)

---

Poorer nations turn to publicly developed GM crops

Article Abstract:

The findings of a study are presented to analyze the existing state of research, regulation, genetic resources, and institutional roles in developing genetically modified (GM) crops. The study would help scientists, policy makers, and regulators understand their respective country's public GM crop research agenda, identify policies, and regulatory needs for specific GM events.

Science & research, Research, Genetically modified crops

Similar abstracts:

• Abstracts: Florida's Natural Au'Some Fruit Juice String Fruit Snacks. Kellogg's American Idol Fruit Snacks. Sahale Snacks
• Abstracts: Planters Nutrition Mix. Cains State Fair Blue Ribbon Pickles
• Abstracts: Iraqi security forces progressing, Rumsfeld says. Marine expert: Pentagon still unready for 'small wars'. Iraqi IEDs limiting movements of U.S. forces: Analyst
• Abstracts: Korean biotechs seize opportunity to list on public markets. Swiss patent proposal prompts criticism
• Abstracts: Great company, bad stock. Bugs or drugs, tortoises or hares? Time to kick that drug habit

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.